Abstract
The transduction of cytotoxic genes by adenoviral vectors into prostatic cells offers a new entity for the treatment of prostate cancer. Current adenoviral vectors cannot infect prostatic cells selectively, and expression of therapeutic genes is often too low to be efficient. Bispecific antibodies may alter the natural tropism of adenoviral vectors towards prostatic cells, and increase the efficacy of infection (transductional targeting). The transcription of transgenes can be placed under the control of prostate-specific promoters (transcriptional targeting), and the combination of this with transductional targeting may be warranted to construct targeted vectors that are adequate for gene therapy of the prostate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bangma, C. Targeting of adenoviral vectors for gene therapy of prostate cancer. Prostate Cancer Prostatic Dis 3, 308–312 (2000). https://doi.org/10.1038/sj.pcan.4500423
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500423
Keywords
This article is cited by
-
Oncolytic viral therapies
Cancer Gene Therapy (2004)
-
Is gene therapy the answer for prostate cancer?
Prostate Cancer and Prostatic Diseases (2004)